Dr. Tiacci on Standard of Care in Hairy Cell Leukemia Treatment
Enrico Tiacci, MD, discusses the current treatment options for patients with hairy cell leukemia. Currently, the standard of care for these patients are purine nucleoside analogs, including pentostatin and cladribine.
Enrico Tiacci, MD, associate professor of hematology, University and Hospital of Perugia, Italy, discusses the current treatment options for patients with hairy cell leukemia in an interview during the 2019 Hairy Cell Leukemia Foundation Annual Conference.
Currently, the standard of care for these patients are purine nucleoside analogs, including pentostatin and cladribine. Both of these agents elicit high complete response rates in the order of 80% to 90%. Additionally, patients with hairy cell leukemia treated with either of these agents have experienced prolonged median responses.
<<< View more from the 2019 Hairy Cell Leukemia Foundation Annual Conference
